Profile of Non-Hemorrhagic Stroke Patients Who Received Endovascular Stenting Services at Dr. Kariadi General Hospital Semarang
Article Sidebar
-
Endovascular stenting, Non-hemorrhagic stroke, Patient profile, Risk factors
Abstract
Highlight:
- This study describes profiles of patients who received endovascular stenting services
- A descriptive method study was selected to offer a thorough overview
ABSTRACT
Introduction: Endovascular stenting (ES) is an alternative therapy to carotid endarterectomy (CEA) and best management therapy (BMT) for intracranial and extracranial arterial stenosis with or without symptoms. Atherosclerosis can cause non-hemorrhagic stroke, and the risk factors include diabetes mellitus, dyslipidemia, smoking, hypertension, and advanced age. Objective: This study aimed to determine the profile of non-hemorrhagic stroke patients who received ES services at Dr. Kariadi General Hospital, Semarang. Method: This research used a descriptive method with sampling carried out sequentially using electronic patient medical record data from January 2023 to November 2024. Result: ES services were obtained for 67 patients, of whom 39 were men (58.2%). The largest age groups were between > 50-60 years and > 60-70 years, accounting for 37.3%. The stenosis in the proximal vertebral artery was performed by ES in 70.1% patients. ES was performed on 62.7% patients, with an average stenosis degree of 59.8% in the 50%–69% range (moderate to severe stenosis group). Risk factors for atherosclerosis in this study included hypertension in 67.2% patients and dyslipidemia in 52.2%. There were 71.6% of patients who did not have risk factors for diabetes mellitus. In this study, only 2 patients’ data from medical records were examined for smoking risk factors. Conclusion: Non-hemorrhagic stroke patients who received endovascular stenting services at Dr. Kariadi General Hospital, Semarang, were men in their 50s and 60s, with lesions in the proximal vertebral artery with an average stenosis degree of 59.8%. Risk factors included hypertension, age, and dyslipidemia.
Full text article
References
1. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128. DOI: 10.1016/S0140-6736(12)61728-0
2. Prasad K, Vibha D, Meenakshi. Cerebrovascular disease in South Asia - Part I: A burning problem. JRSM Cardiovasc Dis. 2012;1(7):1-7. DOI: 10.1258/cvd.2012.012025
3. Bharucha NE, Bharucha EP, Bharucha AE, Bise AV, Schoenberg BS. Prevalence of stroke in the Parsi community of Bombay. Stroke. 1988;19(1):60-2. DOI: 10.1161/01/str.19.1.60
4. Mellière D. Carotid surgery. Assessment and current problems. J Mal Vasc. 1993;18:176–85. Available at: https://pubmed.ncbi.nlm.nih.gov/8254238/
5. Saba L, Saam T, Jäger HR, Yuan C, Hatsukami TS, Saloner D, et al. Imaging biomarkers of vulnerable carotid plaques for stroke risk prediction and their potential clinical implications. Lancet Neurol. 2019;18(6):559–72. DOI: 10.1016/S1474-4422(19) 30035-3
6. Zarins CK. Carotid endarterectomy: The gold standard. J Endovasc Surg. 1996;3(1):10–5. DOI: 10.1177/15 2660289600300106
7. Roederer GO, Langlois YE, Jager KA, Primozich JF, Beach KW, Phillips DJ, ET AL. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits.. Stroke 1984;15(4):605–13. DOI: 10.1161/ 01.str.15.4.605
8. Hennerici M, Hülsbömer HB, Hefter H, Lammerts D, Rautenberg W. Natural history of asymptomatic extracranial arterial disease. Results of a long-term prospective study. Brain. 1987;110(Pt 3):777–91. DOI: 10.1093/brain/110.3.777
9. Gorelick PB, Wong KS, Bae HJ, Pandey DK. Large artery intracranial occlusive disease: A large worldwide burden but a relatively neglected frontier. Stroke. 2008; 39(8): 2396–99. DOI: 10.1161/STROK EAHA.107.505776
10. Hussain M, Datta N, Cheng Z, Dornbos D 3rd, Bashir A, Sultan I, et al. Spanning from the west to east: An updated review on endovascular treatment of intracranial atherosclerotic disease. Aging Dis. 2017;8(2):196-202. DOI: 10.14336/AD.2016.0807
11. Usman FS, Soetanto GW, Ramadhoni PD, Hermawan GA. Numbers of stent and balloon in neuro-endovascular procedures was associated with numbers of stroke risk factors in Indonesia. J Neuro Inter. 2020. Available at: https://scholar.google.com/citations? view_op=view_citation&hl=en&user=f0ds2JQAAAAJ&citation_for_view=f0ds2JQAAAAJ:Tyk-4Ss8FVUC
12. Wabnitz A, Chimowitz M. Angioplasty, stenting and other potential treatments of atherosclerotic stenosis of the intracranial arteries: Past, present and future. J Stroke. 2017;19(3):271–6. DOI: 10.5853/jos.2017.01837
13. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med. 2011;365(11):993–1003. DOI: 10.1065/ NEJMoa1105335
14. Liu L, Wong KSL, Leng X, Pu Y, Wang Y, Jing J, et al. Dual antiplatelet therapy in stroke and ICAS: Subgroup analysis of CHANCE. Neurology. 2015;85(13):1154–62. DOI: 10. 1212/WNL.0000000 000001972
15. Uchiyama S, Sakai N, Toi S, et al. Final results of cilostazol-aspirin therapy against recurrent stroke with intracranial artery stenosis (CATHARSIS). Cerebrovasc Dis Extra 2015;5(1):1–13. DOI: 10.11 59/000369610
16. Gomez CR, Orr SC. Angioplasty and stenting for primary treatment of intracranial arterial stenoses. Arch Neurol. 2001;58(10):1687-90. DOI: 10.1001/ar chneur.58.10.1687
17. Padalia A, Sambursky JA, Skinner C, Moureiden M. Percutaneous transluminal angioplasty with stent placement versus best medical therapy alone in symptomatic intracranial arterial stenosis: A best evidence review. Cureus. 10(7):e2988. DOI: 10.7759 /cureus.2988
18. Cui XP, Lin M, Mu JS, Ye JX, He WQ, Fu ML, et al. Angioplasty and stenting for patients with symptomatic intracranial atherosclerosis: Study protocol of a randomised controlled trial. BMJ Open. 2016; 6(11):e012175. DOI: 10.1136/bmjopen-2016 -012175
19. Sangha RS, Naidech AM, Corado C, Ansari SA, Prabhakaran S. Challenges in the medical management of symptomatic intracranial stenosis in an urban setting. Stroke. 2017;48(8):2158–63. DOI: 10.1161/STROKEAHA.116.016254
20. Lou J, Wang T, Gao P, Krings T, Jiao L. Endovascular treatment of intracranial atherosclerotic stenosis: current debates and future prospects. Front Neurol. 2018;9:666. DOI: 10.3389/fneur.2018.00666
21. Wang Y, Ma Y, Gao P, Chen Y, Yang B, Jiao L. Primary angioplasty without stenting for symptomatic, high-zgrade intracranial stenosis with poor circulation. Am J Neuroradiol. 2018;39(8):1487-92. DOI: 10.3174/ anjr.A5708
22. Zhu Z, Wengui Y. Update in the treatment of extracranial atherosclerotic disease for stroke prevention. Stroke Vasc Neurol. 2019;5(1):65–70. DOI: 10.1136/svn-2019-000261
23. Ritz K, Denswil NP, Stam OC, van Lieshout JJ, Daemen MJ. Cause and mechanisms of intracranial atherosclerosis. Circulation. 2014;130(16):1407-14. DOI: 10.1161/CIRCULATIONAHA.114.011147
24. Li H, Zhang Y, Zhang L, Li Z, Xing P, Zhang Y, et al. Endovaskular treatment of acute ischemic stroke due to intracranial atherosclerotic large vessel occlusion: A systematic review. Clin Neuroradiol. 2020;30:777-87. DOI: 10.1007/s00062-019-00839 -4
25. Hajat C, Dundas R, Stewart AJ, Lawrence E, Rudd AG, Howard R, et al. Cerebrovascular risk factors and stroke subtypes : Differences between ethnic groups. Stroke. 2001;32(1). DOI: 10.1161/01. STR.32.1.37
26. Markus SH, Larsson CS, Kuker W, Schulz GU, Ford I, Rothwell MP, et al. Stenting for symptomatic vertebral artery stenosis: The vertebral artery ischaemia stenting trial. Neurology. 2017;89(12):1229–36. DOI: 10.1212/WNL.0000000 000004385
27. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020-35. DOI: 10.1161/STR.00000000 00000074
28. Cole JW. Large artery atherosclerotic occlusive disease. Continuum (Minneap Minn). 2017; 23 (1, Cerebrovascular Disease):133-157. DOI: 10.1212/ CON.0000000000000436
29. Tzimalos K, Athyros VG, Karagiannis A, Mikhailidis P. Dyslipidemia as a risk factor for ischemic stroke. Curr Top Med Chem. 2009;9(14):1291-7. DOI: 10.2174/ 156802609789869628
30. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377:1319–30. DOI: 10.1056/NEJ Moa1709118
Authors
Copyright (c) 2025 Freddy Hasudungan Aritonang, Aditya Kurnianto, Yovita Andhitara
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.